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Introduction: Among various comorbidities of Human Immunodeficiency Virus-1 (HIV-1) infection male hypogonadism
is very frequent with a prevalence of 19% in patients treated with highly active anti-retroviral therapy (HAART).
Literature data are lacking and achieved by studies with less than 300 subjects each.
Aim of the study: Prevalence and clinical characterization of hypogonadism among a large number of men with
Human Immunodeficiency Virus Infection.
Methods: Endocrinological examination and hormonal screening including serum total testosterone, LH and FSH assays
have been performed in 950 outpatients aged 20-69 years (mean age 45.5 years) at the Metabolic Clinic of Infectious
and Tropical Disease between 2005 and 2009.
Results: Mean serum total testosterone was 470.9±205.5 ng/dl. Considering Endocrine Society threshold for
hypogonadism diagnosis, 15.7% of our patients was hypogonadic (T<300ng/dl); reffering to LH levels 8% of them was
hypogonadotropic, 77.2% was normogonadotropic and 14.8% was hypergonadotropic. According to threshold proposed
by International Society for the Study of the Aging Male (ISSAM) 23.7% of subjects results hypogonadic (T<346ng/dl) of
which 5.8% was hypogonadotropic, 80% normogonadotropic and 14.2% hypergonadotropic.
Table 1
! Endocrine Society (T<300ng/dl) ISSAM (T<346ng/dl)
Percentage of hypogonadism (n
hypogonadic/n total)
15.7% (149/950) 23.7% (225/950)
LH<1.4 mUL/ml 8% (12/149) 5.8% (13/225)
1.4<LH<8.9 mUl/ml 77.2% (115/149) 80% (180/225)
LH>8.9 mUl/ml 14.8 % (22/149) 14.2% (32/225)
Conclusions: Our results demonstrate a prevalence of hypogonadism in HIV patients comparable to older healthy
subjects (19.3% of hypogonadism in patients with mean age 58.7 years; Schneider 2009). This study, which is conduced
on an elevated number of HIV patients, shows that the prevalence of hypogonadism is higher than in general
population. Normogonadotropism predominance in subjects with hypotestosteronemia suggests also a possible
involvement of a pituitary disfunction in the development of hypogonadism.
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